Patent Application
20220298204
The present invention relates to the chemical synthesis of α-amanitin and its derivatives. The present invention also relates to intermediate products of the α-amanitin synthesis.
The objective of the present invention is to provide means and methods to chemically synthesize amanitin or derivatives thereof. This objective is attained by the subject-matter of the independent claims of the present specification.
Amino acid sequences are given from amino to carboxyl terminus. Capital letters for sequence positions refer to
The term “protecting group” in the context of the present specification relates to a moiety covalently attached to a functional group (particularly the carboxylic acid moiety, the amino moiety or the hydroxyl moiety of the molecules discussed herein) that can be selectively attached to the functional group and selectively removed without affecting the integrity or chiral orientation of the carbon backbone of the molecule the protecting group is attached to, nor cleaving particular other protecting groups attached to other protecting groups attached to the molecule.
The term “deprotection agent” in the context of the present specification relates to an agent which is able to cleave a certain protecting group. The skilled person is able to select the deprotection agent according to the protecting group. The conditions under which the protecting group is cleavable constitute the deprotection agent, e.g. if the protecting group is cleavable under acidic conditions, then the deprotection agent is an acid.
The term “preactivated carboxylic group” in the context of the present specification relates to a carboxylic moiety being reacted into an active ester susceptible for the nucleophilic attack of an amine group in order to form a peptide bond.
The term “preactivated amino group” in the context of the present specification relates to an amino group being reacted into a N-trimethylsilyl amine with increased nucleophilicity to attack a carboxylic acid moiety in order to form a peptide bond.
A comprehensive review of modern protecting group chemistry, particularly as it pertains to the compounds disclosed herein, is available in Peter G. M. Wuts, Greene's Protective Groups in Organic Synthesis, 5th Edition, Wiley 2014.
U.S. Pat. No. 6,693,178 B2—“Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries” and US 20160024143 A1—“Deprotection method” are incorporated herein by reference.
Standard convention of organic chemistry, by which a non-designated position in a formula is deemed to be a saturated carbon, is followed herein.
A first aspect of the invention relates to a method for preparation of a compound of formula (Iox)
wherein
a) a compound of formula (IIox)
wherein
X and Y are H, or
Y is OH and X is ORPGP wherein RPGP is a protecting group for phenolic OH groups, particularly a phenolic OH-protecting group not acid- or alkali-labile, more particularly cleavable under reductive conditions, most particularly benzyl (Bn) or
X and Y are selected from F, Cl, Br, and I,
particularly X and Y are H or Y is OH and X is ORPGP
Z and W are H, or
Z is OH and W is ORPGOH, wherein RPGOH is a protecting group for hydroxyl-groups, particularly a hydroxyl-protecting group cleavable with fluoride ions, more particularly TBS, TMS, TES, TBDPS, TIPS, or disiloxane, most particularly TBS,
is reacted with a peptide bond forming reagent,
particularly with a coupling reagent selected from a carbodiimide, an imidazolinium reagent, a phosphonium salt, an organo-phosphorous reagent, an uronium salt, a pyridinium reagent, and a phosphonic acid,
more particularly with HATU [1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate], COMU, HBTU, TBTU, TOMBU, COMBU, or
HCTU,
in a reaction step (a1),
and for Y being OH and/or Z being OH, the compound is reacted with a deprotection agent removing RPGP and/or RPGOH,
or wherein
b) the compound of formula (II)
wherein
X, Y, Z and W have the same meanings as defined above, is reacted with a peptide bond forming reagent,
particularly with HATU
in a reaction step (a2),
yielding a compound of formula (I)
wherein the sulfur atom is subsequently oxidized,
in a reaction step (b2),
and for Y being OH and/or Z being OH, the compound is reacted with a deprotection agent removing RPGP and/or RPGOH, particularly for RPGP with reductive conditions and for RPGOH with fluoride ions,
to yield the compound characterized by (Iox).
For cyclisation, the amide-NH2 of compound (II) or (IIox) does not need to be protected. No significant side reactions were observed without protecting group.
In certain embodiments, the oxidation of the sulfur atom is performed using manganese ions.
In certain embodiments, the chemoselective oxidation of the sulfur atom is performed using a compound of formula (XXII)
with Mn(OTf)2 and H2O2.
In certain embodiments, the chemoselective oxidation of the sulfur atom is performed using PPO (Phthaloyl peroxide), dibenzyolperoxide, tert-butyl peroxybenzoate, or lauroyl peroxide. Preparation of PPO is described in (S. Gan, J. Yin, Y. Yao, Y. Liu, D. Chang, D. Zhu, L. Shi, Org. Biomol. Chem. 2017, 15, 2647-2654.).
In certain embodiments, the oxidation of the sulfur atom is performed with mCPBA (meta-chloroperoxybenzoic acid) in isopropanol/ethanol (8:3).
In certain embodiments, the oxidation of the sulfur atom is performed with an oxaziridinium salt as described in (Rio et al, Org. Lett. 2007, 9,12, 2265-2268).
In certain embodiments, the oxidation of the sulfur atom is performed with non-enantio-selective agents or simply with oxygen or hydrogenperoxide.
In certain embodiments, the oxidation of the sulfur atom is performed with iodine and oxygen.
A second aspect relates to a method for preparation of a compound of formula (I)
wherein a compound of formula (II)
wherein
X and Y are H, or
Y is OH and X is ORPGP wherein RPGP is a protecting group for phenolic OH groups, particularly a phenolic OH-protecting group not acid- or alkali-labile, more particularly cleavable under reductive conditions, most particularly benzyl or
X and Y are selected from F, Cl, Br, and I,
particularly X and Y are H, or Y is OH and X is ORPGP,
Z and W are H, or
Z is OH and W is ORPGOH, wherein RPGOH is a protecting group for hydroxyl-groups, particularly a hydroxyl-protecting group cleavable with fluoride ions, more particularly TBS
is reacted with a coupling reagent selected from a carbodiimide, an imidazolinium reagent, a phosphonium salt, an organo-phosphorous reagent, an uronium salt, a pyridinium reagent, and a phosphonic acid,
particularly with a peptide bond forming reagent,
more particularly with HATU, COMU, HBTU, TBTU, TOMBU, COMBU, or HCTU
in a reaction step (a),
and for Y being OH and/or Z being OH, the compound is reacted with a deprotection agent removing RPGP and/or RPGOH in a reaction step (b)
to yield the compound characterized by (I).
In certain embodiments, a compound of formula (III)
and a compound of formula (IV) or (IVox)
wherein
RNHB is an amino protecting group, particularly an amino protecting group cleavable under alkaline conditions, more particularly Fmoc, or an amino protecting group cleavable with hydrogenolysis, particularly Cbz, most particularly RNHB is Fmoc
W and X have the same meaning as outlined above,
wherein
the amino-group of (IV) or (IVox) is preactivated, particularly with MSA, and preactivated (IV) or preactivated (IVox) and (III) are reacted with a peptide bond forming reagent, particularly with HATU, or
the amino-group of (IV) or (IVox) is preactivated, particularly with MSA, and the carboxyl-group of compound (III) is preactivated, particularly with an O-PFP-ester, O-PCP-ester, or OSu-ester, and preactivated (IV) or preactivated (IVox) and preactivated (III) are reacted in a reaction step (c),
and the compound is reacted with a deprotection agent removing RNHB in a reaction step (d), particularly with a base if RNHB is Fmoc, or with hydrogenolysis if RNHB is Cbz, more particularly with Et2NH, tris-2-amino-ethylamin, DBU, morpholine, or piperidine if RNHB is Fmoc,
to yield the compound characterized by (II) or (IIox).
For coupling compounds (II) and (IV) or (IVox), the acid-COOH group of compound (IV) or (IVox) does not need to be protected. No significant side reactions were observed without protecting group.
In certain embodiments, a compound of formula (IV)
wherein
RCOOX is a carboxyl-protecting group, particularly tButyl,
RNHX is an amino-protecting group, particularly Teoc,
X has the same meaning as outlined above,
wherein the sulfur atom is subsequently oxidized, particularly
and with Mn(OTf)2 and H2O2 in a reaction step (d2),
and the compound is reacted with a deprotection agent removing RCOOX and RNHX,
particularly with a strong acid, more particularly at a pH of −3 to 2, most particularly with 80-95% TFA,
to yield the compound characterized by (IVox).
In certain embodiments, the oxidation of the sulfur atom is performed using manganese ions.
In certain embodiments, the chemoselective oxidation of the sulfur atom is performed using a compound of formula (XXII)
with Mn(OTf)2 and H2O2.
In certain embodiments, the chemoselective oxidation of the sulfur atom is performed using PPO (Phthaloyl peroxide), dibenzyolperoxide, tert-butyl peroxybenzoate, or lauroyl peroxide. Preparation of PPO is described in (S. Gan, J. Yin, Y. Yao, Y. Liu, D. Chang, D. Zhu, L. Shi, Org. Biomol. Chem. 2017, 15, 2647-2654.).
In certain embodiments, the oxidation of the sulfur atom is performed with mCPBA (meta-chloroperoxybenzoic acid) in isopropanol/ethanol (8:3).
In certain embodiments, the oxidation of the sulfur atom is performed with an oxaziridinium salt as described in (Rio et al, Org. Lett. 2007, 9,12, 2265-2268).
In certain embodiments, the oxidation of the sulfur atom is performed with non-enantio-selective agents or simply with oxygen or hydrogenperoxide.
In certain embodiments, the oxidation of the sulfur atom is performed with iodine and oxygen.
In certain embodiments, a compound of formula (V)
wherein
RNHF is an amino protecting group, particularly an amino protecting group cleavable with fluoride ions or strong acids, more particularly Teoc,
RCOOA is a carboxyl-protecting group, particularly a carboxyl-protecting group cleavable under strongly acidic conditions, more particularly tert-butyl,
X has the same meaning as outlined above,
is reacted with a coupling reagent selected from a carbodiimide, an imidazolinium reagent, a phosphonium salt, an organo-phosphorous reagent, an uronium salt, a pyridinium reagent, and a phosphonic acid,
particularly a peptide bond forming reagent, more particularly with T3P, HATU, COMU, HBTU, TBTU, TOMBU, COMBU, or HCTU, in a reaction step (e),
and the compound is reacted with a deprotection agent removing RNHF and RCOOA in a reaction step (f), particularly with TFA,
to yield the compound characterized by (IV).
In certain embodiments, a compound of formula (VI)
and a compound of formula (VII)
wherein
RNHA is an amino protecting group, particularly an amino protecting group cleavable under acidic conditions, more particularly Boc,
RCOOA, RNHF and X have the same meaning as outlined above,
wherein compound (VI) is
preactivated with a peptide bond forming reagent, particularly with HATU, COMU, HBTU, TBTU, TOMBU, COMBU, or HCTU, followed by a reaction with the silylated compound (VII), or
is preactivated as in OSu-ester, followed by a reaction with the compound (VII)
in a reaction step (g),
and the compound is reacted with a deprotection agent removing RNHA in a reaction step (h), particularly with acidic conditions, more particularly at a pH of −3 to 0, even more particularly with HCl or p-toluenesulfonic acid, most particularly with 2 M HCl in Dioxan,
to yield the compound characterized by (V).
In certain embodiments, a compound of formula (VIII)
and a compound of formula (IX)
wherein
RCOOZ is a carboxyl-protecting group, particularly a carboxyl-protecting group cleavable with Zn, more particularly Tce, or RCOOZ is H,
RCOOA, RNHF, RNHA and X have the same meaning as outlined above,
are reacted in a reaction step (i), and if RCOOZ is a carboxyl-protecting group, the compound is reacted with a deprotection agent removing RCOOZ in a reaction step (j), particularly with Zn, to yield the compound characterized by (VI).
A protection group strategy was applied that relies on acid stability. Decreasing pH values were used for deprotection. First, the Tce group of tryptophan (RCOOZ of compound VIII) was removed under reductive conditions using Zn with mildly acidic pH. Afterwards, the Boc group of cysteine (RNHA of compound IX) was removed with p-toluenesulfonic acid. Last, Teoc (RNHF) and tert-butyl (RCOOA) of compound (V) were removed concomitantly with 95% TFA.
In certain embodiments, a compound of formula (X)
and a compound of formula (XI)
and a compound of formula (XII)
wherein
RPep is an active ester, particularly O-pentafluorophenol or OSu-ester,
RNHB is an amino protecting group, particularly an amino protecting group cleavable under alkaline conditions, more particularly Fmoc,
are reacted with solid phase peptide synthesis in a reaction step (k), wherein the carboxyl-group of compound (XII) may be protected,
to yield the compound characterized by (III).
A third aspect relates to a method for preparation of a compound of formula (XIII), (XIIIC), (XIIIN), or (XIIICN)
wherein a compound of formula (XIV)
wherein
RCOOS is a carboxyl-protecting group, particularly a carboxyl-protecting group cleavable with silylating agents, more particularly tert-butyl,
RNHZ is an amino protecting group, particularly an amino protecting group cleavable under alkaline conditions, more particularly Fmoc, or an amino protecting group cleavable under reductive conditions, more particularly trifluoroacetyl;
is reacted with Osmium(IV)-oxide in a reaction step (I), particularly in CHCl3/H2O, and
optionally, the compound is reacted with a deprotection agent removing RNHR and/or RCOOS in a reaction step (m), particularly with silylating agents for RCOOS and reductive conditions or alkaline conditions for RNHR, more particularly with TMSOTf and Lutidine for RCOOS and/or sodium borohydride for RNHZ [if RNHZ is trifluoroacetyl] or alkaline conditions for RNHZ [if RNHZ is Fmoc],
to yield the compound characterized by (XIII), (XIIIC), (XIIIN), or (XIIICN).
When the compound of formula (XIII) is used in the synthesis of α-amanitin or its derivatives, either the deprotection of the amino-protecting group or of the carboxyl-protecting group is omitted, as shown in formula (XIIIC) or (XIIIN). In addition, the OH-groups of compound (XIII) are protected before proceeding with the synthesis.
The oxidation with Osmium(IV)-oxide is particularly stereoselective (2.5:1) in CHCl3/H2O. An Upjohn-dihydroxylation protocol is employed. Only the solvent influences the stereoselectivity here, as in e.g. tBuOH/H2O mainly the opposite diastereomer of compound (XIII) is produced.
A fourth aspect relates to a method for preparation of a compound of formula (XV)
wherein a compound of formula (XVI)
and a compound of formula (XVII) or (XVIIs)
wherein
RNHR an amino protecting group cleavable under reductive conditions, more particularly trifluoroacetyl,
RCOOA is a carboxyl-protecting group, particularly a carboxyl-protecting group cleavable under strongly acidic conditions, more particularly tert-butyl,
are reacted with [(p-cymene)RuCl2]2 in a reaction step (n) yielding the compound (XXIII) or (XXIV)
the compound (XXVI) is reacted with a deprotection agent removing RCOOA in a reaction step (o), and is reacted with acylase in a reaction step (p), or
the compound (XXIII) is reacted with a deprotection agent removing RCOOA in a reaction step (o), and is reacted with a deprotection agent removing RNHR in a reaction step (q), particularly with reductive conditions, more particularly with sodium borohydride, to yield the compound characterized by (XV).
The reaction with acylase in reaction step (p) removes the protecting group RNHR.
In certain embodiments, the compound of formula (XXIII) is directly employed in the synthesis of the compound of formula (XIII), (XIIIC), or (XIIIN) without a deprotection step in between.
The chiral compound (XV) may be gained directly from the reaction with [(p-cymene)RuCl2]2. The reaction is particularly stereoselective when compound (XVIIs) is employed. Then, compound (XXIII) is gained and no acylase step is necessary. Stereoselectivity is improved compared to methods known from literature (e.g. A. Bayer, U. Kazmaier, Org. Lett. 2010, 12, 21, 4960-4963).
Otherwise, when using compound (XVII), compound (XXIV) in an 1:1 mixture of the (R,R) and the (S,S) diastereomers is gained. From this mixture, the correct diastereomer [compound (XV)] is gained with the use of acylase.
A fifth aspect relates to a method for preparation of a compound of formula (XVIII)
wherein a compound of formula (XIX)
and a compound of formula (XX)
wherein
RPGP is a protecting group for phenolic OH groups, particularly a phenolic OH-protecting group not acid- or alkali-labile, more particularly cleavable under reductive conditions, most particularly benzyl,
are reacted with Ni2+ in a reaction step (r)
to yield the compound characterized by (XVIII).
A sixth aspect relates to a method for preparation of a compound of formula (Iox), wherein a compound of formula (I)
wherein the sulfur atom is oxidized,
yielding the compound (Iox).
In certain embodiments, the oxidation of the sulfur atom is performed using manganese ions. In certain embodiments, the chemoselective oxidation of the sulfur atom is performed using a compound of formula (XXII)
with Mn(OTf)2 and H2O2.
In certain embodiments, the chemoselective oxidation of the sulfur atom is performed using PPO (Phthaloyl peroxide), dibenzyolperoxide, tert-butyl peroxybenzoate, or lauroyl peroxide. Preparation of PPO is described in (S. Gan, J. Yin, Y. Yao, Y. Liu, D. Chang, D. Zhu, L. Shi, Org. Biomol. Chem. 2017, 15, 2647-2654.).
In certain embodiments, the oxidation of the sulfur atom is performed with mCPBA (meta-chloroperoxybenzoic acid) in isopropanol/ethanol (8:3).
In certain embodiments, the oxidation of the sulfur atom is performed with an oxaziridinium salt as described in (Rio et al, Org. Lett. 2007, 9, 12, 2265-2268).
In certain embodiments, the oxidation of the sulfur atom is performed with non-enantio-selective agents or simply with oxygen or hydrogenperoxide.
In certain embodiments, the oxidation of the sulfur atom is performed with iodine and oxygen.
In certain embodiments, the method according to the third aspect is applied for the method of the first aspect. Compound (X) can be obtained from compound (XIII).
In certain embodiments, the method according to the fourth aspect is applied for the method of the third aspect. Compound (XIV) can be obtained from compound (XV).
In certain embodiments, the method according to the fifth aspect is applied for the method of the first aspect. Compound (VIII) can be obtained from compound (XVIII).
A seventh aspect of the invention relates to a method for preparation of a compound of formula (XXIII) or (XXIIIox)
wherein a compound of formula (IV) or (IVox), respectively,
and a compound of formula (X)
wherein X, W, and RNHB have the same meanings as defined above, wherein the amino-group of (IV) or (IVox) is preactivated, particularly with MSA, and preactivated (IV) or preactivated (IVox) and (X) are reacted with a peptide bond forming reagent, particularly with HATU, COMU, HBTU, TBTU, TOMBU, COMBU, or HCTU, more particularly with COMU, in a reaction step (s) to yield the compound (XXIII) or (XXIIIox), respectively.
An eighth aspect of the invention relates to a method for preparation of a compound of formula (XXVI) or (XXVIox)
wherein a compound of formula (XXVIII) or (XXVIIIox), respectively,
and a compound of formula (XXV)
wherein
X, W, and RNHB have the same meanings as defined above,
RNHB2 is an amino-protecting group, particularly an amino-protecting group cleavable under acidic conditions, more particularly Boc;
RCOOY is a carboxyl-protecting group, particularly fluorenylmethyl or benzyl, more particularly fluorenylmethyl;
wherein (IV) or (IVox) and (XXV) are reacted with a peptide bond forming reagent, particularly with HATU, COMU, HBTU, TBTU, TOMBU, COMBU, or HCTU, in a reaction step (t) to yield the compound (XXVI) or (XXVIox), respectively.
A ninth aspect of the invention relates to a method for preparation of a compound of formula (XXVII) or (XXVIIox)
wherein
a compound of formula (IV) or (IVox),
and a compound of formula (X)
wherein X, W, and RNHB have the same meanings as defined above,
wherein the amino-group of (IV) or (IVox) is preactivated, particularly with MSA, and preactivated (IV) or preactivated (IVox) and (X) are reacted with a peptide bond forming reagent, particularly with COMU, in a reaction step (s) to yield the compound (XXIII) or (XXIIIox), respectively,
and subsequently compound (XXIII) or (XXIIIox) and compound (XXV) are reacted with a peptide bond forming reagent, particularly with HATU, COMU, HBTU, TBTU, TOMBU, COMBU, or HCTU
in a reaction step (u) to yield the compound (XXVII) or (XXVIIox), respectively;
or
compound (XXIII) or (XXIIIox) and compound (XXV) are reacted with a peptide bond forming reagent, particularly with HATU, COMU, HBTU, TBTU, TOMBU, COMBU, or HCTU in a reaction step (u) to yield the compound (XXVII) or (XXVIIox), respectively;
or
a compound of formula (XXVIII) or (XXVIIIox), respectively,
and a compound of formula (XXIX)
wherein
X, W, and RNHB have the same meanings as defined above,
RNHB2 is an amino-protecting group, particularly an amino-protecting group cleavable under acidic conditions, more particularly Boc;
wherein RCOOY is a carboxyl-protecting group, particularly fluorenylmethyl or benzyl, more particularly fluorenylmethyl;
wherein (XXVIII) or (XXVIIIox) and (XXV) are reacted with a peptide bond forming reagent, particularly with HATU, COMU, HBTU, TBTU, TOMBU, COMBU, or HCTU,
in a reaction step (t) to yield the compound (XXVI) or (XXVIox), respectively
and subsequently compound (XXVI) or (XXVIox) and compound (X) are reacted with a peptide bond forming reagent, particularly with HATU, in a reaction step (v) to yield the compound (XXVII) or (XXVIIox), respectively
or
compound (XXVI) or (XXVIox) and compound (X) are reacted with a peptide bond forming reagent, particularly with HATU, in a reaction step (v) to yield the compound (XXVII) or (XXVIIox), respectively.
A tenth aspect of the invention relates to a method for preparation of a compound of formula (I) or (Iox), wherein a compound of formula (XXVII) or (XXVIIox) prepared according to the ninth aspect
is reacted with a coupling reagent selected from a carbodiimide, an imidazolinium reagent, a phosphonium salt, an organo-phosphorous reagent, an uronium salt, a pyridinium reagent, and a phosphonic acid,
particularly a peptide bond forming reagent, more particularly with T3P, HATU, COMU, HBTU, TBTU, TOMBU, COMBU, or HCTU,
to yield compound (I) or (Iox).
A further aspect relates to a compound of the general formula (I)
wherein
Y is H and Z is H,
Y is H and Z is OH,
Y is OH and Z is H
Y is F, Cl, I or Br and Z is OH, or
Y is F, Cl, I or Br and Z is H;
particularly Y and Z are independently selected from OH and H.
A further aspect relates to a compound of the general formula (II)
wherein
X is H and W is H,
X is OH and W is OH,
X is H and W is OH,
X is OH and W is H,
X is F, Cl, I or Br, and W is OH, or
X is F, Cl, I or Br, and W is H;
particularly X and W are independently selected from OH and H.
A further aspect relates to a compound of the general formula (IIox)
wherein
X is H and W is H,
X is OH and W is OH,
X is H and W is OH,
X is OH and W is H,
X is F, Cl, I or Br, and W is OH, or
X is F, Cl, I or Br, and W is H;
particularly X and W are independently selected from OH and H.
A further aspect relates to a compound of the general formula (IVox)
wherein
X is H or OH, or
X is F, Cl, I or Br
particularly X is selected from OH and H.
A further aspect relates to a compound of the general formula (XXVIII)
wherein
X is H and W is H,
X is OH and W is OH,
X is H and W is OH,
X is OH and W is H,
X is F, Cl, I or Br, and W is OH, or
X is F, Cl, I or Br, and W is H;
particularly X and W are independently selected from OH and H.
A further aspect relates to a compound of the general formula (XXVIIIox)
wherein
X is H and W is H,
X is OH and W is OH,
X is H and W is OH,
X is OH and W is H,
X is F, Cl, I or Br, and W is OH, or
X is F, Cl, I or Br, and W is H;
particularly X and W are independently selected from OH and H.
A further aspect relates to a compound of the general formula (XXVI)
wherein
particularly X is H and W is H, or X is H and W is OH, or X is OH and W is H
A further aspect relates to a compound of the general formula (XXVIox)
wherein
particularly X and W are independently selected from OH and H.
The invention is further illustrated by the following examples and figures, from which further embodiments and advantages can be drawn. These examples are meant to illustrate the invention but not to limit its scope.
9 Step Synthesis Via Ruthenium-Catalyzed Allylic Alkylation
The (2S,3R,4R)-4,5-dihydroxyisoleucine derivative 13 was synthesized in 9 steps (
Separation of the desired
Asymmetric Synthesis Strategies Via Regioselective Ruthenium-Catalyzed Allylic Alkylation and Possible Shortcuts
In order to achieve a higher overall yield of the synthesis route described in the previous section a chiral alkylating reagent during the allylic alkylation reaction was used (
The overall synthesis strategy for the enantiomerically pure Fmoc-protected (2S,3R,4R)-4,5-dihydroxyisoleucine derivative (
The diastereomeric ratio (dr) was calculated to be 86:14 towards the (2R,3S)-diastereomer and 99:1 towards the (2S,3R)-configured diastereomer. The former was separated conveniently by the following acylase reaction which led to the formation of a enantiomerically pure didehydroisoleucine 7 with a dr of 99:1. Because of the enantiomeric purity the asymmetric dihydroxylation also resulted in a higher yield as there were only two diastereomers that needed separation afterwards instead of four. The overall yield starting from glycine tert-butyl ester (1) after 9 steps was calculated to be 17-21%.
The high enantiomeric excess of 5 also made it possible to take two shortcuts resulting in a higher yield (
One shortcut was the direct Tfa-deprotection of didehydroisoleucine 5 followed by Fmoc-protection. This way, the tBu-cleavage and reattachment was omitted resulting in the formation of the dihydroxylation substrate within two steps instead of four. The enantiomeric excess of 13 following shortcut 1 was calculated by chiral HPLC and resulted to be 95%. The overall yield was calculated to be 24-29%.
A second shortcut was the direct Sharpless dihydroxylation of the allylic alkylation product 5 followed by the protection of the side chain with the TBS protecting groups. The diastereomers were separated by column chromatography on silica gel after cleavage of the Tfa protecting group using LiOH and Fmoc-protection of the C-terminus (11). The enantiomeric excess of 13 following shortcut 2 was calculated by chiral HPLC and resulted to be 70%. Both shortcuts enable the synthesis of Fmoc-4,5-dihydroxyisoleucine in 7 steps instead of 9 and provided higher overall yields.
The (S)-6-hydroxytryptophan derivative 33 was synthesized in four steps, starting with an alkylation of the commercially available 6-benzoxyindol (29) using
1H NMR (400 MHz, DMSO-d6): δ (ppm)=1.79 (s, 3H) 2.92 (dd, J=14.68, 8.66 Hz, 1H) 3.09 (dd, J=14.68, 4.89 Hz, 1H) 4.42 (td, J=8.22, 5.14 Hz, 1H) 5.09 (s, 2H) 6.72 (d, J=6.27 Hz, 1H) 6.89 (d, J=2.01 Hz, 1H) 6.98 (d, J=2.01 Hz, 1H) 7.27-7.33 (m, 1H) 7.35-7.41 (m, 3H) 7.42-7.48 (m, 2H) 8.11 (d, J=7.78 Hz, 1H) 10.64 (s, 1H).
13C NMR (100 MHz, DMSO-d6): δ (ppm)=173.59, 169.20, 154.45, 137.68, 136.67, 128.39, 127.62, 127.48, 122.27, 121.85, 118.78, 110.00, 109.21, 95.95, 69.49, 52.98, 27.22, 22.42.
HRMS (ESI): m/z calc. für C20H20N2O4 (M+H)+353.1496, found 353.1487.
1H NMR (500 MHz, CDCl3): δ (ppm)=1.27-1.39 (m, 1H) 1.61-1.74 (m, 2H) 1.76-1.88 (m, 1H) 2.00-2.13 (m, 1H) 2.71-3.05 (m, 4H) 3.23 (dd, J=14.65, 3.97 Hz, 1H) 4.01 (d, J=12.51 Hz, 1H) 4.20 (t, J=4.65 Hz, 1H) 5.00 (s, 2H) 6.55 (d, J=2.44 Hz, 1H) 6.62-6.74 (m, 2H) 6.79 (s, 1H) 6.88 (d, J=1.83 Hz, 1H) 7.03 (dd, J=9.31, 2.44 Hz, 1H) 7.12 (d, J=8.70 Hz, 1H) 7.16-7.33 (m, 7H) 7.34-7.57 (m, 5H) 8.09 (d, J=9.31 Hz, 3H) 8.38 (br. s., 1H) 8.80 (d, J=1.68 Hz, 1H).
13C NMR (100 MHz, CDCl3): δ (ppm)=179.92, 156.24, 141.28, 137.77, 137.47, 135.19, 134.01, 133.58, 133.51, 132.64, 131.17, 130.41, 130.04, 129.64, 129.32, 128.84, 128.13, 127.73, 125.83, 124.16, 123.53, 123.36, 120.68, 110.92, 110.18, 96.86, 71.78, 70.98, 63.47, 58.66, 30.95, 22.83.
HRMS (ESI): m/z calc. C43H35Cl3N4NiO4 (M+H)+835.1150, found 835.1159.
The dr was determined by chiral HPLC with a CHIRALPAK AD-H column (hexane/isopropanol=55/45, λ=280 nm, 0.8 mL/min). tR (major diastereomer)=13.29 min, >99:1 dr, tR(minor diastereomer)=17.28 min.
HRMS (ESI): m/z calc. C18H18N2O3(M+H)+ 311.1390, found 311.1391.
Synthesis of the Peptide Building Blocks
The thioether building units 40 and 41 were readily established by treatment of a fully protected L-cystine derivative (35) with sulfuryl chloride. Cleavage of the disulfide afforded the highly reactive sulfenyl chloride monomer 36, which in the following step is susceptible for an electrophilic aromatic substitution (SEAr) either solely N-terminally protected or fully protected 6-hydroxytryptophan and tryptophan derivative 38 and 39. The use of the TCE-protecting group at the C-terminus helped to suppress the formation of undesired side-products with residual sulfuryl chloride from the sulfenyl chloride formation, but was not imperative for the reaction to take place (
The tripeptide building block H-Gly-Ile-Gly-OH (45) was synthesized in solution phase by first synthesizing a N-terminally Cbz- and C-terminally Bn-protected tripeptide, followed by simultaneous Cbz- and Bn-deprotection by hydrogenolysis using H2 and Pd/C as catalyst. (
The Fmoc-Asn-Hyp-DHIL(TBS)2-OH tripeptide 48 was synthesized on solid phase using the CTC-resin. The use of Fmoc-Asn-OPfp (47) during the coupling of asparagine with no protecting group at the side chain suppressed the formation of the dehydration product (a tripeptide containing Fmoc-p-cyanoalanine) to the extent of only 10% (
A C-terminally 9-Fluorenylmethyl ester-protected dipeptide building block 66 was synthesized by esterification of trans-N-(Boc)-4-hydroxy-L-proline (63) with 9-fluorenylmethanol affording fully protected 4-hydroxy-L-proline 64. Boc-deprotection under acidic conditions, followed by coupling with Boc-Asn-OH using EDC and HOBt and repeated Boc-deprotection under acidic conditions led to the formation of dipeptide building block 66 with no formation of the dehydration side product present.
Assembly of the Peptide Building Blocks Towards (S)-Deoxy-(O)-Benzyl α-amanitin and (S)-Deoxy Amaninamide.
First, monocyclic thioethers 55 and 56 were synthesized in order to obtain the bicyclic structures of (S)-Deoxy (O)-benzyl-α-amanitin and (S)-Deoxy amaninamide (
A second pathway leading to the formation of (S)-Deoxy-(O)-benzyl-α-amanitin and (S)-Deoxy amaninamide was the direct coupling of DHIL-derivative 13 to the fully deprotected monocyclic pentapeptides 55 and 56 by using a silylating agent for the N-terminus of the pentapeptides and an active ester forming agent for the carboxylic function of the DHIIe derivative, analogous to the method described above. Monocyclic hexapeptides 67 and 68 could then be coupled to the C-terminally Fm-protected dipeptide building block 66 leading to the formation monocyclic octapeptides 69 and 70. The final cyclization was then performed after simultaneous Fmoc and Fm-cleavage and subsequent TBS-deprotection from the DHIL residue.
Sulfide Oxidation Affording α-Amanitin and Amaninamide
The asymmetric oxidation of the tryptathionine moiety leading to (O)-Benzyl-α-amanitin and amaninamide (62) was achieved by using a manganese complex as a catalyst with a porphyrine inspired chiral ligand, following a protocol reported by Gao et al (D. Wen, L. Jun, S. Gao, Org. Lett. 2013, 15, 22, 5658-61). Hydrogenolysis with H2 and Pd/C of (O)-Benzyl-α-amanitin in THF afforded the natural product α-amanitin (61) after 30 min of reaction time.
Materials and Methods
To a solution of glycine tert-butyl ester hydrochloride (10.0 g, 137 mmol, 1.00 eq) in MeOH (150 ml) triethylamine (17.4 ml, 125 mmol, 2.10 eq) was added dropwise. After stirring for 5 min ethyl trifluoroacetate (16.4 ml, 137 mmol, 2.3 eq) was added and the mixture was stirred for 16 h at room temperature during which time a clear solution formed. Then, the reaction mixture was concentrated under reduced pressure and the resulting residue acidified with 2 N HCl before being extracted with EtOAc (3×100 ml). The organic layers were combined, then washed with sat. NaHCO3 (2×100 ml), distilled H2O (2×100 ml) and brine (2×100 ml) and dried over MgSO4. The solvent was removed in vacuo to give the product (2) as a yellow oil (13.5 g, quant.).
1H NMR (CDCl3-d1, 400 MHz): δ=1.50 (s, 9H), 4.02 (d, J=5.02 Hz, 2H), 6.89 ppm (br s, 1H).
13C NMR (CDCl3-d1, 100 MHz): δ=27.91, 41.94, 83.52, 115.60 (q, J=287.28 Hz), 157.06 (q, J=39.60 Hz), 167.28 ppm.
HRMS (ESI): m/z calculated: C8H12F3NO3(M−H)− 226.0686, found 226.0693.
But-3-en-2-ol (1.50 g, 20.8 mmol, 1.00 eq) was added slowly to a solution of NaH (1.50 g, 62.4 mmol, 3.00 eq) in dry THF (40 ml) at 0° C. Then Boc2O (5.9 g, 27 mmol, 1.3 eq) was added in portions over 10 min under vigorous stirring at this temperature. The reaction mixture was allowed to warm to room temperature overnight and then diluted with Et2O after 16 h of vigorous stirring. Excess sodium hydride was quenched by the slow addition of water. The resulting mixture was then extracted with diethyl ether (3×50 ml). The combined organic extracts were washed with brine (1×50 ml), dried over MgSO4 and concentrated under reduced pressure.
After purification by column chromatography on silica gel (hexane/EtOAc, 10:1) the product (4) was obtained as a colourless liquid (3.6 g, 20.3 mmol, quant.).
1H NMR (CDCl3-d1, 400 MHz): δ=1.36 (d, J=6.53 Hz, 3H), 1.49 (s, 9H), 5.13-5.17 (m, 2H), 5.25-5.31 (m, 1H), 5.83-5.91 ppm (m, 1H).
13C NMR (CDCl3-d1, 100 MHz): δ=19.72, 27.48, 73.72, 81.62, 115.78, 137.78, 137.17, 152.53 ppm.
HRMS (ESI): m/z calculated: C9H16O3(M+H)+ 173.1172, found 173.1171.
LHMDS (1 M in THF, 11 mmol, 2.5 eq) was added slowly to a solution of trifluoroacetyl glycine tert-butylester (2, 1.0 g, 4.4 mmol, 1.5 eq) in dry THF (12 ml) at −78° C. After stirring for 10 min a solution of dried ZnCl2 (720 g, 5.30 mmol, 1.20 eq) in dry THF (6 ml) was added at this temperature and stirring was continured for another 30 min at −78° C. Meanwhile a solution was prepared from [(p-cymene)RuCl2]2 (37 mg, 0.06 mmol, 0.02 eq) and triphenylphosphine (32 mg, 0.12 mmol, 0.04 eq) in dry THF (6 ml) and stirred for 10 min at room temperature. Then, the allylic carbonate (4) (517 mg, 3.00 mmol, 1.00 eq) was added and the resulting solution was added to the chelated enolate at −78° C. The reaction mixture was allowed to warm to room temperature overnight. After diluting with EtO2 (100 ml) the reaction mixture was hydrolyzed by addition of 1 M KHSO4 until the precipitate was fully dissolved in the organic layer. Then, the layers were separated, the aqueous layer was extracted with diethyl ether (3×50 ml) and the combined organic layers were washed with brine (100 ml) and dried over MgSO4. The solvent was removed in vacuo and the crude product was purified by column chromatography on silica gel (hexane/EtOAc, 10:1), which afforded the product (5) as a colourless oil (740 mg, 88%).
1H NMR (CDCl3-d1, 400 MHz): δ=1.10 (d, J=7.03 Hz, 3H), 1.49 (s, 9H), 2.82-2.89 (m, 1H), 4.48-4.54 (m, 1H), 5.07-5.20 (m, 2H), 5.70 (s, 1H), 6.70 ppm (d, J=7.53 Hz, 1H).
13C NMR (CDCl3-d1, 100 MHz): δ=15.75, 27.97, 40.21, 56.71, 83.35, 117.15 (q, J=273.2 Hz), 117.46, 136.78, 157.03 (q, J=39.60 Hz), 168.89 ppm.
Fully protected didehydroisoleucine (5) (1.0 g, 3.6 mmol, 1.0 eq) was dissolved in a solution of 95% TFA in DCM. After stirring for 2 h at room temperature the solvent was evaporated in vacuo to afford the trifluoroacetylated didehydroisoleucine (6) (800 mg, quant.) as a white solid.
1H-NMR (400 MHz, CDCl3): δ (ppm)=6.63 (br, 1H), 5.66-5.77 (m, 1H) 5.19-5.27 (m, 2H), 4.66 (q, J=4.2 Hz, 1H), 2.90-2.99 (m, 1H), 1.15 (d, J=7.04 Hz, 3H)
13C-NMR (100 MHz, CDCl3): δ (ppm)=175.37, 157.67, 136.37, 118.37, 117.00, 56.43, 39.56, 16.32
HRMS (ESI): m/z calc for C8H9F3NO3 (M−H)− 224.0529, found 224.0536.
To a solution of the racemic trifluoroacetylated didehydroisoleucine 6 (700 mg, 3.10 mmol, 1.00 eq) in Sørensen phosphate buffer (15 ml, pH 7.5) 4 M KOH (777 μl, 3.10 mmol, 1.00 eq) and acylase I from Aspergillus melleus (300 mg) was added. After 6 h at 36° C. the reaction mixture was filtered through a Amicon Ultra centrifugal filter unit (cut off 10 kDa). The resulting the amino acid buffer mixture was then submitted to the subsequent Fmoc protection without any further purification.
HRMS (ESI): m/z calc for C6H11NO2 (M+H)+ 130.0863, found 130.0858.
To a stirring solution of 4,5-didehydroisoleucine 8 in Sørensen phosphate buffer (15 ml) was added a solution of Fmoc-OSu (823 mg, 2.44 mmol, 1.05 eq) in acetone (10 ml). After stirring for 16 h the reaction mixture was diluted with 50 ml water, acidified to pH 2 with 1 N HCl and extracted with ethyl acetate (3×30 ml). The combined organic layers were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (1% MeOH/DCM) to obtain the Fmoc didehydroisoleucine 8 as a white solid (810 mg, 75%, 2 steps).
1H-NMR (400 MHz, DMSO-d6): δ (ppm)=8.49 (br, 1H), 7.68 (d, J=7.5 Hz, 2H), 7.44-7.54 (m, 2H), 7.32 (t, J=7.02 Hz, 2H), 7.23 (t, J=7.02 Hz, 2H), 5.45-5.73 (m, 1H), 5.18-5.32 (m, 1H), 5.01-5.17 (m, 1H), 4.30-4.37 (m, 2H), 4.12-4.19 (m, 1H), 2.39-2.54 (m, 1H), 2.44-2.52 (m, 1H), 1.60 (d, J=6.0 Hz, 2H), 1.05 (d, J=7.0 Hz, 1H)
13C-NMR (100 MHz, DMSO-d6): δ (ppm)=177.01, 156.04, 143.58, 141.45, 137.20, 130.67, 127.93, 127.02, 125.20, 124.13, 120.18, 117.60, 67.46, 58.04, 53.33, 47.25, 39.65, 35.09
HRMS (ESI): m/z calc for C21 H21NO4 (M+H)+ 374.1363, found 374.1360.
BF3*OEt2 (1.69 ml, 13.7 mmol, 6.0 eq) was added to a stirring solution of Fmoc-protected 4,5-didehydroisoleucine (8) (800 mg, 2.28 mmol, 1.00 eq) in 10 ml tBuOAc. The reaction mixture was stirred at rt for 5 min, then cooled to 0° C. and neutralized with saturated NaHCO3. The reaction mixture was then extracted with EtOAc (3*50 ml), washed with 1 M HCl (3×20 ml) and brine (2×20 ml) and dried over MgSO4. After evaporation of the solvent under reduced pressure the crude product was purified by column chromatography on silica gel (hexane/EtOAc, 10:1) to obtain the fully protected 4,5-didehydroisoleucine (9) as a colourless oil (650 mg, 70%).
1H NMR (400 MHz, CDCl3): δ (ppm)=1.07-1.14 (m, 3H), 1.49 (s, 9H), 2.74-2.85 (m, 1H), 4.21-4.34 (m, 2H), 4.39 (m, J=6.90, 6.90 Hz, 2H), 5.08-5.18 (m, 2H), 5.24 (s, 1H), 5.68-5.79 (m 1H), 7.33 (t, J=7.53 Hz, 2H), 7.41 (t, J=7.53 Hz, 2H), 7.61 (d, J=7.53 Hz, 2H), 7.78 (d, J=7.53 Hz, 2H)
13C NMR (100 MHz, CDCl3): δ (ppm)=15.66, 27.75, 40.07, 46.86, 58.02, 66.69, 81.93, 116.32, 119.64, 124.81, 126.72, 127.36, 137.45, 140.97, 143.56, 155.92, 170.27
HRMS (ESI): m/z calc for C26H29NO4 (M+H)+ 430.1989, found 430.1982.
N-methylmorpholine-N-oxide (287 mg, 2.45 mmol, 1.30 eq) was added to a stirring solution of 9 and potassium osmate dihydrate (45.2 mg, 122 μmol, 0.05 eq) in 15 ml of a 4:1 mixture of CHCl3 and water and stirred for 20 min at rt. Then, Fmoc-protected 4,5-dihydroxyisoleucine tent-butyl ester (10) (1.00 g, 2.45 mmol, 1.00 eq) was added to the biphasic mixture. The resulting mixture was stirred at rt for 16 h and diluted with 100 ml DCM. Afterwards, saturated sodium metabisulfite solution (20 ml) was added and extracted with DCM (3×10 ml) after being stirred for 30 min. the combined organic phases were dried over NaSO4 and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel (0.6% MeOH/DCM to 1.0% MeOH/DCM gradient) to obtain the 4,5-dihydroxyisoleucine derivative 10 as white crystals (439 mg, 40%).
1H NMR (CDCl3-d1, 400 MHz): δ=1.00 (d, J=7.03 Hz, 3H), 1.50 (s, 9H), 1.94-2.04 (m, 3H), 3.57 (dd, J=10.79, 3.01 Hz, 1H), 3.72 (t, J=9.50 Hz, 1H), 3.76-3.82 (m, 1H), 4.18-4.27 (m, 2H), 4.37-4.47 (m, 2H), 5.90 (d, J=8.28 Hz, 1H), 7.33 (t, J=7.03 Hz, 2H), 7.41 (t, J=7.28 Hz, 2H), 7.61 (d, J=7.28 Hz, 2H), 7.77 ppm (d, J=7.53 Hz, 2H)
13C NMR (CDCl3-d1, 100 MHz): δ=10.41, 27.99, 38.32, 47.14, 57.85, 64.71, 67.18, 71.70, 82.74, 119.96, 125.02, 127.06, 127.71, 141.27, 143.63, 156.82 ppm
HRMS (ESI): m/z calc for C25 H31NO6 (M+H)+ 442.2224, found 442.2222.
tert-butyl(2S,3R,4R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4,5-bis((tert-butyldimethylsilyl)oxy)-3-methylpentanoate (11)
Under a nitrogen atmosphere tert-butyldimethylsilyl chloride (546 mg, 3.62 mmol, 8.0 eq) was added to a stirring solution of Fmoc-4,5-dihydroxyisoleucine tert-butyl ester (10, 200 mg, 452 μmol, 1.00 eq) in 4 ml of a 1:1 mixture of dry DMF and pyridine. Then, DMAP (8.3 mg, 68 μmol, 0.15 eq) was added and the resulting mixture was stirred for 24 h at rt. Afterwards, the reaction mixture was diluted with 50 ml EtOAc and washed with 1 M HCl (3×20 ml) and brine (2×20 ml), dried over MgSO4 and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel (hexane/EtOAc, 19:1) to obtain the fully protected 4,5-dihydroxyisoleucine (9) as a colourless oil (271 mg, 90%).
1H NMR (CDCl3-d1, 500 MHz): δ=0.06-0.09 (m, 6H), 0.11 (s, 3H), 0.17 (s, 3H), 0.90-0.95 (m, 18H), 1.00 (d, J=7.02 Hz, 3H), 1.49 (s, 9H), 2.35-2.44 (m, 1H), 3.44 (dd, J=9.69, 8.32 Hz, 1H), 3.52-3.57 (m, 1H), 3.82-3.86 (m, 1H), 4.19-4.26 (m, 2H), 4.39 (d, J=7.02 Hz, 2H), 5.99 (d, J=8.24 Hz, 1H), 7.30 (t, J=7.78 Hz, 2H), 7.40 (t, J=7.40 Hz, 2H), 7.63 (dd, J=9.77, 7.78 Hz, 2H), 7.76 (d, J=7.63 Hz, 2H)
13C NMR (CDCl3-d1, 126 MHz): −5.50, −5.38, −4.64, −4.09, 10.40, 18.05, 18.26, 25.87, 25.90, 28.04, 35.51, 47.27, 59.12, 64.18, 66.80, 73.74, 81.38, 119.88, 125.20, 126.98, 127.55, 141.28, 144.02, 144.17, 156.46, 171.22
HRMS (ESI): m/z calculated: C37H59NO6Si2(M+H)+ 670.3953, found 670.3945.
A solution of fully protected 4,5-dihydroxyisoleucine 11 (100 mg, 149 μmol, 1.0 eq) was dissolved in 2 ml dry DCM, treated with 2,6 lutidine (173 μl, 1.49 mmol, 10.0 eq) and cooled to 0° C. Then, TMSOTf (135 μl, 746 μmol, 5.0 eq) was added and the reaction mixture was allowed to warm to room temperature overnight. The solution was diluted with Et2O (10 ml) followed by the addition of Sørensen phosphate buffer (pH=7; 5 ml). Afterwards, the pH of the mixture was adjusted to 2 by the dropwise addition of NaHSO4-solution (10%). The phases were separated and the aqueous phase was extracted with Et2O (3×10 ml). The combined organic phases were washed with brine, dried over NaSO4 and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel (1% MeOH/DCM) to furnish the final product (13) as a colourless oil (90.5 mg, quant.).
1H NMR (CDCl3-d1, 500 MHz): δ=0.02-0.14 (m, 12H), 1.04 (d, J=7.02 Hz, 3H), 2.36-2.47 (m, 1H), 3.55 (t, J=8.24 Hz, 1H), 3.58-3.64 (m, 1H), 3.79-3.88 (m, 1H), 4.24 (t, J=6.79 Hz, 1H), 4.37-4.49 (m, 3H), 6.10 (d, J=7.32 Hz, 1H), 7.31 (t, J=7.48 Hz, 2H), 7.40 (t, J=7.32 Hz, 2H), 7.61 (t, J=7.63 Hz, 2H), 7.76 (d, J=7.48 Hz, 2H)
13C NMR (CDCl3-d1, 126 MHz): −5.48, −5.41, −4.74, −4.07, 11.07, 18.00, 18.25, 25.79, 25.87, 37.01, 47.23, 57.77, 64.68, 67.00, 73.97, 119.95, 125.05, 125.12, 127.03, 127.64, 141.33, 143.86, 156.43
HRMS (ESI): m/z calculated: C33H51NO6Si2 (M+H)+ 614.3328, found 614.3324.
A flame dried flask was charged with 10 g of crushed activated 3 Å molecular sieves and flushed with nitrogen for several minutes. Then, DCM (200 ml) was added and the flask was cooled to −20° C. (+)-Diisopropyl tartrate (DIPT) (1.75 g, 7.49 mmol, 0.06 eq), crotyl alcohol (9.00 g, 125 mmol, 1.00 eq) and Ti(OiPr)4 (1.77 g, 6.24 mmol, 0.05 eq) were added sequentially at this temperature. The resulting mixture was stirred for 15 min at −20° C., then a solution of tert-butyl hydroperoxide (TBHP, 5 M in DCM) (50.0 ml, 150 mmol, 2.00 eq) was added dropwise. The reaction mixture was stirred for 2 h at this temperature. Careful quenching of the excess TBHP was carried out by careful addition of trimethyl phosphite (22.0 ml, 187 mmol, 1.50 eq) at −20° C. after which trimethyl amine (26.1 ml, 187 mmol, 1.50 eq), DMAP (1.83 g, 15.0 mmol, 0.12 eq) and a solution of p-toluenesulfonyl chloride (23.8 g, 125 mmol, 1.00 eq) in DCM (100 ml) was added sequentially. The temperature was raised to −10° C. and the reaction mixture stirred for 36 h. Afterwards the mixture was filtered through a pad of Celite and washed with DCM. The filtrate was then washed with 10% tartaric acid (2×100 ml), saturated NaHCO3 (2×100 ml) and brine (2×100 ml). The organic phase was dried over MgSO4 and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel (hexane/EtOAc, 2:1) and recrystallized (Et2O/hexane) in order to afford the tosylate (S,S-19))) as white needles (20.2 g, 67%).
1H NMR (CDCl3-d1, 400 MHz): δ=1.30 (d, J=5.27 Hz, 3H), 2.46 (s, 3H), 2.87-2.94 (m, 1H), 2.92 (s, 1H), 3.98 (dd, J=11.42, 5.90 Hz, 1H), 4.18 (dd, J=11.42, 3.89 Hz, 1H), 7.36 (d, J=8.28 Hz, 2H), 7.80 ppm (d, J=8.53 Hz, 2H).
13C NMR (CDCl3-d1, 100 MHz): δ=16.95, 21.64, 52.77, 55.45, 70.03, 127.94, 129.89, 132.70, 145.06 ppm.
HRMS (ESI): m/z calculated: C11H14O4S (M+H)+ 243.0686, found 243.0678.
A solution of tosylate (S,S)-19 in dry THF (20 ml) was added to a suspension of Zinc-Copper-couple (6 g) and dry NaI (22.3 g, 149 mmol, 3.00 eq) in dry THF (150ml). The resulting suspension was stirred for 2 h at 70° C., cooled to room temperature and filtered through a pad of silica. Afterwards the THF-butenol mixture was distilled under reduced pressure (200 mbar, 100° C.) while the collecting flask was cooled to −78° C. (dry ice). The THF-butenol solution was then submitted to the next step without further purification.
The butenol-THF solution of cooled to 0° C. and NaH (5.82 g, 145 mmol, 3.00 eq) was carefully added under a nitrogen atmosphere in small portions. Then Boc2O (11.7 g, 53.4 mmol, 1.1 eq) was added in portion-wise over 10 min under vigorous stirring at this temperature. The reaction mixture was allowed to warm to room temperature overnight and then diluted with Et2O after 16 h of vigorous stirring. Excess sodium hydride was quenched by the slow addition of water. The resulting mixture was then extracted with diethyl ether (3×50 ml). The combined organic extracts were washed with brine (1×50 ml), dried over MgSO4 and concentrated under reduced pressure. After purification by column chromatography on silica gel (hexane/EtOAc, 10:1) the product (S)-4 was obtained as a colourless liquid (6.25 g, 75% two steps).
A suspension of
A suspension of 30 (1.03 g, 3.32 mmol) in 40% NaOH (H2O/MeOHv/v=1:1, 14 mL/mmol) was stirred at 110° C. for 4 h, neutralized with conc. HCl to pH=7 and the solvent was removed in vacuo. The crude product was dissolved in MeOH (20 mL/mmol) and Ni(OAc)2*6 H2O (966 mg, 3.32 mmol) and (S)-28 (1.78 g, 3.65 mmol) were added followed by K2CO3 (2.09 g, 15.1 mmol). The resulting mixture was refluxed for 16 h and the precipitate was filtered of and washed with DCM. The solvent of the filtrate was removed in vacuo and the crude product was suspended in DCM, washed with H2O and dried with Na2SO4. After removal of the solvent in vacuo the crude product was purified with DCM/MeOH (v/v=40:1) to give the product 32 as an orange solid (2.44 g, 88%).
To a solution of 32 (180 mg, 0.51 mmol) in MeOH was added 6 M HCl (15 mL) The solution was stirred for 45 min at 70° C. and conc. NH4OH-solution was added until pH=7 was reached. The aqueous layer was washed with EtOAc (2×15 mL), and the pH was adjusted to 10. The precipitate was centrifuged and washed two times with water (pH=10), to give (S)-6-benzoxytryptophan as a white solid.
Triethylamine (446 μL g, 3.22 mmol, 2.00 eq.) and TeocOSu (626 mg, 2.42 mmol, 1.50 eq.) was added successively to a solution of L-6-benzoxytryptophan (33, 0.5 g, 1.61 mmol, 1.00 eq.) in DMF (20 mL). The reaction mixture was stirred at r.t. for 2 h, then concentrated under reduced pressure. The aqueous layer was carefully acidified to pH=4 by dropwise addition of 1
HRMS (ESI): m/z calc. for C17H24N2O4Si (M+H)+ 455.1997, found 455.1999.
Triethylamine (11.3 mL g, 80.9 mmol, 1.5 eq.) and TeocOSu (18.2 g, 70.0 mmol, 1.30 eq.) was added successively to a solution of
HRMS (ESI): m/z calc. for C17H24N2O4Si (M+H)+ 349.1578, found 349.1582.
To a solution of N-Teoc protected
HRMS (ESI): m/z calc. for C19H25Cl3N2O4Si (M+H)+ 479.0722, found 479.0721.
To a solution of compound 33a (1.0 g, 2.2 mmol, 1.0 eq.) in DCM (8.8 mL) at 0° C. was added DMAP (40.3 mg, 0.329 mmol, 0.15 eq.) and EDC*HCl (548 mg, 2.86 mmol, 1.30 eq.) successively. After stirring at 0° C. for 10 min 2,2,2-trichloroethanol (0.42 mL, 4.4 mmol, 2.00 eq.) was added and the solution was stirred for 2 h at r.t. The reaction mixture was diluted with DCM (50 mL), washed with 0.5 M HCl (2×25 mL), sat. NaHCO3 solution (25 mL) and brine (25 mL). After drying over Na2SO4 and removal of the solvent under reduced pressure the crude product was purified by column chromatography on silica gel (0.5% MeOH/DCM) to afford compound 39 as a yellow oil (1.1 g, 85%).
HRMS (ESI): m/z calc for C26H31Cl3N2O5Si (M+H)+ 585.1141, found 585.1139.
Synthesis of (N-Boc)2-cystine-(OtBu)2 (35)
A solution of
HRMS (ESI): m/z calc for C24H44N2O8S2 (M+H)+ 553.2612, found 553.2615.
To a solution of (N-Boc)2-
HRMS (ESI): m/z calc. for C38H52Cl3N3O9SSi (M+H)+ 860.2332, found 860.2323.
To a solution of (N-Boc)2-
HRMS (ESI): m/z calc. for C3H46Cl3N3O8SSi (M+H)+ 754.1913, found 754.1917.
A solution of tryptathionine derivative 39 (1.63 mmol, 1.00 eq.) in DMF (8.4 mL) was treated with CH3COOH (0.8 mL) and zinc (3.51 g, 53.6 mmol, 33.0 eq.) for 2 h at 45° C. The reaction mixture was filtered over Celite and the solvent was removed under reduced pressure. The crude product was dissolved in EtOAc (50 mL) and washed with 10% KHSO4 solution (2×25 mL) and brine (2×25 mL). After drying over Na2SO4 and removing of the solvent under reduced pressure, the crude product was purified by C18 reverse phase chromatography (AcN/H2O 50% to 100% gradient) to give compound 49 as a yellow solid (840 mg, 83% over 2 steps).
HRMS (ESI): m/z calc. for C36H51N3O9SSi (M+H)+ 730.3183, found 730.3188.
A solution of tryptathionine derivative 38 (9.15 mmol, 1.00 eq.) in DMF (40 mL) was treated with CH3COOH (4 mL) and zinc (20.0 g, 302 mmol, 33.0 eq.) for 2 h at 45° C. The reaction mixture was filtered over Celite and the solvent was removed under reduced pressure. The crude product was dissolved in EtOAc (200 mL) and washed with 10% KHSO4 solution (2×50 mL) and brine (2×50 mL). After drying over Na2SO4 and removing of the solvent under reduced pressure, the crude product was purified by C18 reverse phase chromatography (AcN/H2O 50% to 100% gradient) to afford compound 50 as a yellow oil (5.0 g, 88%. over 2 steps).
HRMS (ESI): m/z calc. for C31H46Cl3N3O8SSi (M+H)+ 624.2769, found 624.2775.
To a solution of Cbz-glycine (42, 10.0 g, 32.7 mmol, 1.00 eq.) in acetone (100 mL) was added a suspension of
HRMS (ESI): m/z calc. for C16H22N2O5 (M+H)+ 323.1601, found 323.1606.
Glycyl-L-isoleucylglycine (45)
Dipeptide 44 (10.1 g, 31.3 mmol, 1.00 eq.) and benzyl glycinate (8.21 g, 40.7 mmol, 1.30 eq.)
were dissolved in dry DMF (125 mL). Then, COMU (17.4 g, 40.7 mmol, 1.30 eq.) and DIPEA (12.6 mL, 72.1 mmol, 3.00 eq.) were added at 0° C. The reaction mixture was allowed to warm to r.t. overnight and diluted with EtOAc (300 mL) afterwards. After washing with a solution of 10% KHSO4-solution (2×100 mL) the fully protected tripeptide precipitated in the organic phase. The organic phase was cooled to 4° C. for 4 h in order for the peptide to precipitate, then the precipitate was filtered and washed with cold EtOAc. The precipitate was redissolved in a 1:1 mixture of water and THF (260 mL). Pd/C (1 g) was added to the solution after degassing with N2 for 30 min. Then, the reaction mixture was degassed with hydrogen for 1 h. After vigorous stirring at room temperature under 1.0 atm of hydrogen overnight, the catalyst was filtered through a pad of Celite. Afterwards, the mixture was concentrated under reduced pressure to obtain the product 45 as a white solid (5.71 g, 74%)
HRMS (ESI): m/z calc. for C10H19N3O4 (M+H)+ 246.1448, found 246.1440.
Synthesis of Pentapeptide 51:
A solution of thioether building block 49 (111 mg, 0.14 mmol, 1.00 eq.) in AcN (0.7 mL) was treated with collidine (37 μL, 0.27 mmol, 2.0 eq) and N,N′-disuccinimidyl carbonate (39 mg, 0.15 mmol, 1.1 eq.) and stirred for 1 h at r.t. A solution of tripeptide 45 (44 mg, 0.18 mmol, 1.3 eq) in a 1:4 mixture of AcN/H2O (1 mL) was added and the reaction mixture was stirred for 2 h at r.t. Afterwards, the mixture was diluted with EtOAc (20 mL), 10% KHSO4-solution (20 mL) was added and the aqueous layer was extracted with EtOAc (2×20 mL). The organic layer was washed with brine (2×20 mL), dried over Na2SO4 and evaporated under reduced pressure which afforded pentapeptide 51 as a yellow solid (115 mg, 90%).
HRMS (ESI): m/z calc. for C46H68N6O12SSi (M+H)+ 957.4458, found 957.4457.
Synthesis of Pentapeptide 52:
A solution of tryptathionine building block 50 (2.0 g, 2.5 mmol, 1.0 eq.) in AcN (10 mL) was treated with collidine (659 μL, 4.95 mmol, 2.00 eq) and N,N′-disuccinimidyl carbonate (697 mg, 2.72 mmol, 1.10 eq.) and stirred for 1 h at r.t. A solution of tripeptide 45 (790 mg, 3.22 mmol, 1.30 eq.) in a 1:4 mixture of AcN/H2O (18 mL) was added and the reaction mixture was stirred for 2 h at r.t. Afterwards, the mixture was diluted with EtOAc (100 mL), 10% KHSO4-solution (20 mL) was added and the aqueous layer was extracted with EtOAc (2×50 mL). The organic layer was washed with brine (2×50 mL), dried over Na2SO4 and evaporated under reduced pressure which afforded pentapeptide 52 as a yellow solid (2.15 g, 93%).
HRMS (ESI): m/z calc. for (M+H)+ C36H51Cl3N6O11S 851.4039, found 851.4058.
Fully Protected Cyclic Pentapeptide 53:
Pentapeptide 51 (151 mg, 0.180 mmol, 1.00 eq.) was dissolved in 1 mL of a solution of p-toluenesulfonic acid in THF (1.8
HRMS (ESI): m/z calc. for C41H58N6O9SSi (M+H)+ 839.3828, found 839.3839.
Fully Protected Cyclic Pentapeptide (54):
Pentapeptide 52 (700 mg, 0.822 mmol, 1.00 eq.) was dissolved in 10 mL of 2 M HCl in dioxane and stirred for 40 min at r.t. Then, the reaction mixture diluted with 40 mL of dioxane and the solvent was evaporated under reduced pressure. The precipitate was dissolved in 8 mL DMF and diluted with 82 mL DCM. Afterwards, DIPEA (279 μL, 1.64 mmol, 2.00 eq.) and T3P (50% in EtOAc, 977 μL, 1.64 mmol, 2.00 eq.) were added. After the solution was stirred for 5 h at r.t., ⅓ of the the solvent was concentrated under reduced pressure. The organic phase was washed with 10% KHSO4-solution (20 mL), sat. NaHCO3-solution (20 mL), water (20 mL) and brine (20 mL). The organic layer was dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product was purified by C18 reverse phase chromatography (AcN/H2O 50% to 100% gradient) to afford cyclic pentapeptide 54 as a yellow solid (420 mg, 72%).
HRMS (ESI): m/z calc. for C34H52N6O8SSi (M+H)+ 733.3409, found 733.3409.
Fully Deprotected Monocyclic Pentapeptide 55:
Monocyclic Pentapeptide 53 (125 mg, 0.17 mmol, 1.00 eq.) was stirred in TFA/DCM/TIPS (8:1.5:0.5) for 2 h at r.t. The solvent was removed under reduced pressure and the crude product was purified by C18 reverse phase chromatography (AcN/H2O 20% to 100%) to afford the fully deprotected monocyclic pentapeptide 55 as a white powder (100 mg, quant.).
HRMS (ESI): m/z calc. for C31H38N6O7S (M+H)+ 639.2595, found 639.2590.
Fully Deprotected Monocyclic Pentapeptide 56:
Monocyclic Pentapeptide 54 (250 mg, 0.34 mmol, 1.00 eq.) was stirred in TFA/DCM/TIPS (8:1.5:0.5) for 2 h at r.t. The solvent was removed under reduced pressure and the crude product was purified by C18 reverse phase chromatography (AcN/H2O 10% to 30%) to afford the fully deprotected monocyclic pentapeptide 56 as a white powder (200 mg, quant.).
HRMS (ESI): m/z calc. for C24H32N6O6S (M+H)+ 533.2177, found 533.2188.
Tripeptide (48):
HRMS (ESI): m/z calc. for C42H64N4O10Si2 (M+H)+ 841.4233, found 841.4253.
Monocyclic Octapeptide 57:
A solution of fully deprotected monocyclic pentapeptide 55 (50.0 mg, 0.078 mmol, 1.00 eq.) and MSA (13.8 μL, 0.86 mmol, 1.1 eq.) in DMA (1.5 mL) was stirred for 2 h at 50° C. Separately, a solution of Fmoc-Asn-Hyp-DHIIe(TBS)2-OH (98.8 mg, 0.12 mmol, 1.50 eq.), COMU (36.9 mg, 0.086 mmol, 1.10 eq.) and DIPEA (15.0 μL, 0.083 mmol, 1.10 eq.) in DMA (0.4 mL) was stirred for 30 min at 0° C. The silylated monocyclic peptide was then added to the activated tripeptide and stirred for 1 h at 0° C. then at 35° C. for 3 h. Et2NH (82.0 μL, 0.078 mmol, 10.0 eq.) was added and stirred for 1 h at r.t. The solvent was removed under reduced pressure and the crude product was purified using preparative HPLC (Sunfire Prep C18 OBD 10 μm, 50×150 mm column, gradient A) to afford octapeptide 57 as a white solid (65.5 mg, 68%).
HRMS (ESI): m/z calc. for C58H90N10O14SSi2 (M+H)+ 1239.5970, found 1239.5980.
Monocyclic Octapeptide 58:
A solution of fully deprotected monocyclic pentapeptide 56 (40.0 mg, 0.075 mmol, 1.00 eq.) and MSA (12 μL, 0.075 mmol, 1.00 eq.) in DMA (1.5 mL) was stirred for 2 h at 50° C. Similtaneously, a solution of Fmoc-Asn-Hyp-DHIIe(TBS)2-OH (95 mg, 0.11 mmol, 1.50 eq.), COMU (35.0 mg, 0.083 mmol, 1.10 eq.) and DIPEA (14.0 μL, 0.083 mmol, 1.10 eq.) in DMA (0.4 mL) was stirred for 30 min at 0° C. The silylated monocyclic peptide was then added to the activated tripeptide and stirred for 1 h at 0° C. then at 35° C. for 3 h. Et2NH (77 μL, 0.75 mmol, 10 eq.) was added and stirred for 2 h at r.t. The solvent was removed under reduced pressure and the crude product was purified using preparative HPLC (Sunfire Prep C18 OBD 10 μm, 50×150 mm column, gradient A) to afford octapeptide 58 as a white powder (70 mg, 68%).
HRMS (ESI): m/z calc. for C51H84N10O13SSi2 (M+H)+ 1133.5551, found 1133.5549.
Monocyclic Octapeptide 59:
A solution of TBAF in THF (1
HRMS (ESI): m/z calc. for C46H62N10O14S (M+H)+ 1011.4240, found 1001.4247.
Monocyclic Octapeptide 60:
A solution of TBAF in THF (1
HRMS (ESI): m/z calc. for C39H56N10O13S (M+H)+ 905.3822, found 905.38113.
2-((9H-fluoren-9-yl)methyl) 1-(tert-butyl) (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate (64):
A solution of N-Boc-protected (2S,4R)-4-hydroxyproline 63 (5.0 mg, 22 mmol, 1.0 eq.) in DMF (20 mL) was added dropwise to a solution of 9-Fluorenemethanol (8.5 mg, 43 mmol, 2.0 eq.), EDC*HCl (8.3 g, 43 mmol, 2.0 eq.) and DMAP (396 mg, 3.24 mmol, 0.150 eq.) in DCM (220 mL). The reaction mixture was stirred at r.t. for 2 h. Then, 10% KHSO4 solution (50 mL) was added. The organic phase was washed with brine (50 mL) and dried over NaSO4. Afterwards, the solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel (hexane/ethyl acetate=1:1) to afford compound 64 as a white solid (5.0 g, 56%).
(9H-fluoren-9-yl)methyl (2S,4R)-4-hydroxypyrrolidine-2-carboxylate (64a):
64 (5.0 g, 22 mmol, 1.0 eq.) was treated with 4 M HCl in Dioxane (30 mL) at r.t. for 1 h. Afterwards, the solvent was evaporated under reduced pressure to afford the product (64a) as a white solid (3.7 g, quant.).
HRMS (ESI): m/z calc. for C19H19NO3 (M+H)+ 310.1438, found 310.1426.
N-Boc-protected asparagine (1.7 g, 7.3 mmol, 1.5 eq.), 64a (1.5 g, 4.8 mmol, 1.0 eq.), EDC*HCl (1.4 g, 7.3 mmol, 1.5 eq.) and HOBt*H2O (1.5 g, 9.7 mmol, 2.0 eq.) were dissolved in DMF (72 mL) and stirred at r.t. for 16 h. The reaction mixture was diluted with EtOAc (200 mL). Then, 10% KHSO4 solution (50 mL) was added. The organic phase was washed with 10% KHSO4 solution (50 mL) and brine (2×50 mL). After drying over NaSO4 and removal of the solvent under reduced pressure the crude product was purified by C18 reversed phase chromatography (AcN/H2O 20% to 70%) to afford dipeptide 65 as a white powder (1.6 g, 78%).
HRMS (ESI): m/z calc. for C28H33N3O7(M+H)+ 524.2391, found 524.2396.
65 (1.0 g, 1.9 mmol, 1.0 eq.) was treated with 4 M HCl in Dioxane (30 mL) at r.t. for 1 h. Afterwards, the solvent was evaporated under reduced pressure to afford the product (66) as a white solid (870 mg, quant.).
HRMS (ESI): m/z calc. for C23H25N3O5(M+H)+ 424.1866, found 424.1858.
Monocyclic Hexapeptide 67:
A solution of fully deprotected monocyclic pentapeptide 55 (42 mg, 0.66 mmol, 1.00 eq.) and MSA (11.6 μL, 0.723 mmol, 1.10 eq.) in DMA (2 mL) was stirred for 2 h at 50° C. Simultaneously, a solution of Fmoc-DHIIe(TBS)2-OH (13, 52 mg, 0.85 mmol, 1.30 eq.), COMU (36 mg, 0.85 mmol, 1.30 eq.) and DIPEA (15 μL, 0.85 mmol, 1.30 eq.) in DMA (0.4 mL) was stirred for 30 min at 0° C. The silylated monocyclic peptide was then added to the activated dihydroxyisoleucine derivative and stirred for 1 h at 0° C. then at r.t. overnight. Afterwards, the mixture was diluted with EtOAc (50 mL) and washed with 10% KHSO4 solution (3×5 mL). The organic phase was washed with brine (2×20 mL), dried over NaSO4 and evaporated under reduced pressure. The crude product of 67 was used in the next step without any further purification.
HRMS (ESI): m/z calc. for C64H87N7O12SSi2 (M+H)+ 1234.5745, found 1234.5745.
Monocyclic Hexapeptide 68:
A solution of fully deprotected monocyclic pentapeptide 56 (100 mg, 0.188 mmol, 1.00 eq.) and MSA (33.2 μL, 0.207 mmol, 1.10 eq.) in DMA (4 mL) was stirred for 2 h at 50° C. Simultaneously, a solution of Fmoc-DHIIe(TBS)2-OH (13, 149 mg, 0.244 mmol, 1.30 eq.), COMU (104 mg, 0.244 mmol, 1.30 eq.) and DIPEA (42.5 μL, 0.244 mmol, 1.30 eq.) in DMA (1.25 mL) was stirred for 30 min at 0° C. The silylated monocyclic peptide was then added to the activated dihydroxyisoleucine derivative and stirred for 1 h at 0° C. then at r.t. overnight. Afterwards, the mixture was diluted with EtOAc (100 mL) and washed with 10% KHSO4 solution (3×10 mL). The organic phase was washed with brine (2×25 mL), dried over NaSO4 and evaporated under reduced pressure. The crude product of 68 was used in the next step without any further purification.
HRMS (ESI): m/z calc. for C57H81N7O11SSi2 (M+H)+ 1128.5326, found 1128.5316.
Monocyclic Octapeptide 69:
Crude monocyclic hexapeptide 67 (0.66 mmol, 1.0 eq.), dipeptide 66 (42 mg, 0.10 mmol, 1.50 eq.) were dissolved in DMF (1.5 mL). Then, DIPEA (17.3 mL, 0.10 mmol, 1.50 eq.) and HATU (38 mg, 0.10 mmol, 1.5 eq) were added at 0° C. The reaction mixture was allowed to warm to r.t. overnight and concentrated under reduced pressure. The crude product was purified by C18 reversed phase chromatography (AcN/H2O 60% to 100%) to fully protected octapeptide 69 as a white solid (60 mg, 55% over two steps).
HRMS (ESI): m/z calc. for C87H110N10O16SSi2 (M+H)+ 1639.7433, found 1639.7404.
Monocyclic Octapeptide 70:
Crude monocyclic hexapeptide 68 (0.188 mmol, 1.00 eq.), dipeptide 68 (119 mg, 0.282 mmol, 1.50 eq.) were dissolved in DMF (3 mL). Then, DIPEA (49.1 mL, 0.282 mmol, 1.50 eq.) and HATU (108 mg, 0.282 mmol, 1.50 eq) were added at 0° C. The reaction mixture was allowed to warm to r.t. overnight and concentrated under reduced pressure. The crude product was purified by C18 reversed phase chromatography (AcN/H2O 60% to 100%) to fully protected octapeptide 70 as a white solid (170 mg, 59% over two steps).
HRMS (ESI): m/z calc. for C80H104N10O15SSi2 (M+H)+ 1533.7015, found 1533.7004.
Monocyclic Octapeptide 71:
Monocyclic octapeptide 69 (15 mg, 10.3 μmol, 1.00 eq.) was dissolved in DMF (0.1 mL). Et2NH (10.8 μL, 0.103 mmol, 10 eq.) was added and stirred for 2 h at r.t. The solvent was removed under reduced pressure and the precipitate was redissolved in THF (0.2 mL). Then, a solution of TBAF in THF (1
HRMS (ESI): m/z calc. for C46H62N10O14S (M+H)+ 1011.4240, found 1001.4241.
Monocyclic Octapeptide 72:
Monocyclic octapeptide 69 (20.0 mg, 14.8 μmol, 1.00 eq.) was dissolved in DMF (0.15 mL). Et2NH (15.5 μL, 0.148 mmol, 10 eq.) was added and stirred for 2 h at r.t. The solvent was removed under reduced pressure and the precipitate was redissolved in THF (0.3 mL). Then, a solution of TBAF in THF (1
HRMS (ESI): m/z calc. for C39H56N10O13S (M+H)+ 905.3822, found 905.3810.
(S)-Deoxy-(O)-benzyl-α-amanitin (61a):
Monocyclic octapeptide 59 or 71 (20.0 mg, 19.2 μmol, 1.00 eq.) was dissolved in DMF (19 mL). Then, DIPEA (6.71 μL, 38.5 μmol, 2.00 eq.) and HATU (4.98 mg, 38.5 μmol, 2.00 eq) were added at 0° C. The reaction mixture was allowed to warm to r.t. overnight and concentrated under reduced pressure. The crude product was purified using preparative HPLC (Sunfire Prep C18 OBD 10 μm, 50×150 mm column, gradient C) to afford (O)-Benzyl-α-amanitin (61-a, 13 mg, 68%) as a white powder.
HRMS (ESI): m/z calc. for C46H60N10O13S (M+H)+ 993.4135, found 993.4145.
(S)-Deoxyamaninamide (72a):
Monocyclic octapeptide 60 or 72 (20.0 mg, 21.4 μmol, 1.00 eq.) was dissolved in DMF (21 mL). Then, DIPEA (7.47 μL, 42.9 μmol, 2.00 eq.) and HATU (16.3 mg, 42.9 μmol, 2.00 eq) were added at 0° C. The reaction mixture was allowed to warm to r.t. overnight and concentrated under reduced pressure. The crude product was purified using preparative HPLC (Sunfire Prep C18 OBD 10 μm, 50×150 mm column, gradient B) to afford (S)-Deoxyamaninamide (72a, 14 mg, 74%) as a white powder.
HRMS (ESI): m/z calc. for C39H54N10O12S (M+H)+ 887.3716, found 887.3718.
The prophyrine derived ligand (22 μg, 0.45 μmol, 0.3 eq.) and MnOTf2 (16 μg, 0.45 μmol, 0.3 eq.) were dissolved in DCM (1 mL) and stirred for 3 h at r.t. Then Octapeptide 61a (1.5 mg, 1.5 μmol, 1.0 eq.) dissolved in DMF (500 μL), AcOH (0.21 μL, 3.8 μmol, 2.5 eq.) and H2O2 (0.11 μL, 4.5 μmol, 3.0 eq.) were added. The reaction mixture was cooled down to 0° C. and was stirred for 16 h at 0° C. The solvent was removed under reduced pressure and the crude product was used in the next step without further purification.
HRMS (ESI): m/z calc. for C46H60N10O14S (M+H)+ 1009.4084 found 1009.4118.
Amaninamide (62):
The prophyrine derived ligand (73 μg, 1.5 μmol, 0.3 eq.) and MnOTf2 (53 μg, 1.5 μmol, 0.3 eq.) were dissolved in DCM (1 mL) and stirred for 3 h at r.t. Then Octapeptide 72 (5 mg, 5 μmol, 1.0 eq.) dissolved in DMF (500 μL), AcOH (0.700 μL, 12.7 μmol, 2.5 eq.) and H2O2 (0.37 μL, 15.0 μmol, 3.0 eq.) were added. The reaction mixture was cooled down to 0° C. and was stirred for 16 h at 0° C. The solvent was removed under reduced pressure and the crude product was purified using preparative HPLC (Sunfire Prep C18 OBD 10 μm, 50×150 mm column, gradient D) to afford amaninamide 62 as a white powder.
HRMS (ESI): m/z calc. for C39H54N10O13S (M+H)+, found.
α-Amanitin (61):
The crude product of 61b was dissolved in THF/H2O (2:1) and Pd/C (1 mg) was added. The reaction mixture was flushed with N2 for 10 min, then with H2 for 10 min and was stirred for 2 h at r.t. The solvent was removed under reduced pressure and the crude product was purified using preparative HPLC (Sunfire Prep C18 OBD 10 μm, 50×150 mm column) to afford α-Amanitin (61) as a white powder.
HRMS (ESI): m/z calc. for C39H54N10O14S (M+H)+ 919.3614 found 919.3614.
Preparative HPLC Purification Gradients:
Gradient A: 0-25 min 40%-60% B, 25-35 min 100% B; 35-40 min 40% B 0.1% formic acid in water (Solvent A) and 0.1% formic acid in ACN (Solvent B).
Gradient B: 0-30 min 10%-30% B, 30-40 min 100% B; 40-50 min 10% B 0.1% formic acid in water (Solvent A) and 0.1% formic acid in ACN (Solvent B).
Gradient C: 0-60 min 5%-50% B, 60-65 min 100% B; 65-70 min 5% B 0.1% formic acid in water (Solvent A) and 0.1% formic acid in ACN (Solvent B).
Solid-Phase Peptide Synthesis
Automated or manual solid-phase peptide synthesis was performed in 50 μmol scale. Loading: To a 10 ml syringe reactor with frit and cap 1 g of tritylchloride polystyrene (TCP) resin (0.9 mmol/g) were added and 7 ml drydichloromethane (DCM). For resin loading with the first amino acids, the resin was pre-swollen for 10 min and the solvent was removed by evaporation in vacuum. A mixture of the amino acids (0.6 mmol) and 3 equivalents of N,N-diisopropylamine (DIPEA) dissolved in 5 ml dry DCM was added to the resin. The syringe was agitated for 30 min at room temperature. The solution was removed and the resin was washed (2×5 ml N,N-dimethylformamide(DMF), 2×5 ml DCM). Capping of non-reacted functional groups of the resin was performed with DCM, methanol and DIPEA 80:15:5 (2×10 ml, 10 min). After washing (5×5 ml DMF), Fmoc-removal was achieved with DMF/piperidine (4:1, 5 ml, 1×2 min, 1×20 min). After final washing (2×5 ml DMF, 1×5 ml methanol, 3×5 ml DCM), the resin was dried in vacuo. Coupling of Fmoc protected amino acids: To 200 mg of the resin (˜0.5 mmol/g), a 0.25M solution of the amino acid in DMF (2.5 eq relative to resin loading) was added. After addition of a 0.5M solution of DIPEA in DMF (2.5 eq) and a 0.25 M solution of O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate TBTU in DMF (2.5 eq), the reaction solution was mixed for 15 min. A second coupling was performed for 15 min. Fmoc removal: DMF/piperidine (4:1, 2.5 ml) was added to the resin and mixed for 2.5 min. The procedure was repeated 4 times. The resin was washed with DMF (6×2.5 ml). After the final coupling cycle, the resin was washed with DCM (6×2 ml). Cleavage: After addition of the cleavage cocktail (DCM/HFIP 4:1, the syringe was shaken for 30 min. The solution was transferred to a flask and the solvent was removed in vacuo. Further instructions can be found in (Amblard M, Fehrentz J A, Martinez J, Subra G. Mol Biotechnol. 2006 July; 33(3):239-54).
Abbreviations
BF3*Et2O: boron trifluoride etherate
Bn: benzyl
Boc: tert-butyloxycarbonyl
BMIM-PF6: 1-butyl-3-methylimidazolium hexafluorophosphate
Cbz: benzyloxycarbonyl
COMBU: 4-{[1,3-Dimethyl-2,4,6-trioxotetrahydropyrimidin-5(6H)ylidenaminooxy](dimethylamino)methylen}morpholin-4-iumhexafluorophosphate
COMU: (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium-hexafluorophosphate
[(p-cymene) RuCl2]2: (cymene)ruthenium dichloride dimer
DCM: dichloromethane
DHIL: dihydroxy-isoleucine
DIPEA: N,N-diisopropylethylamine
DMA: dimethylacetamide
DMF: dimethylformamide
(DHQD)2PHAL: hydroquinidine 1,4-phthalazinediyl diether
Fm-9-Fluorenylmethyl
Fmoc: fluorenylmethyloxycarbonyl
Fmoc-OSu: 9-Fluorenylmethyl N-succinimidyl carbonate
HATU: 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium
HBTU: 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-hexafluorophosphate
HCTU: 2-(6-Chlor-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium-hexafluorophosphate
Hyp: trans-4-hydroxy-proline
LHMDS: lithium bis(trimethylsilyl)amide
MSA: N-Methyl-N-trimethylsilylacetamid
NMO: 4-methylmorpholine 4-oxide
PPh3: triphenylphosphine
PPO: Phthaloyl peroxide
T3P: 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide
TBAF: tetra-n-butylammonium fluoride
tBuOAc: tert-butyl-acetate
TBS: tert.-butyldimethylsilyl
TBTU: 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate
Tce: trichloroethyl
Teoc: 2-(Trimethylsilyl)ethoxycarbonyl
TFA: trifluoroacetic acid
THF: tetrathydrofuran
TMSOTf: trimethylsilyl trifluoromethanesulfonate
TOMBU: N-{[1,3-Dimethyl-2,4,6-trioxotetrahydropyrimidin-5(6H)-ylidenaminooxy](dimethylamino)methylen}-N-methylmethanaminiumhexafluorophosphate
| Number | Date | Country | Kind |
|---|---|---|---|
| 19184833.2 | Jul 2019 | EP | regional |
| 19197390.8 | Sep 2019 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2020/068902 | 7/3/2020 | WO |
